drugset / Trial / NCT05665751
A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.
Timeline
- Start
- 2023-03-08
- Primary completion
- 2024-09
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TLC-3595 | Unknown | — | Oral |
Indications
No indication recorded.